|
♦ this month’s deep dive
The Great Ingredients Breakup: Why $20B+ of Assets Are in Motion
In the food industry’s reformulation, the durable money sits one layer below the brand. Within a single fortnight, a private equity sponsor and a strategic acquirer paid up for that layer from opposite sides of the deal table. The mechanism differed. The logic did not.
The consumer story in food is loud and brand-level: less sugar, more protein, cleaner labels, shorter ingredient lists. The investable story is quieter and sits one layer down, with the companies that supply the texturants, sweetener systems, fibers, and emulsifiers that make reformulation possible. Two transactions in the space of about two weeks turned that layer into the most interesting real estate in the sector, and they did so from opposite sides of the table.
Start with the seller. In late May, IFF agreed to sell its Food Ingredients division to the private markets manager CVC Capital Partners for $4.3 billion, roughly ten times the unit’s EBITDA. This was not a distressed sale. The division, which spans texturants, emulsifiers, plant-based solutions, and cultures, generated about $3.1 billion of revenue in 2025, and IFF has guided to $10.5 to $10.8 billion in full-year 2026 revenue with the division still inside the group ahead of an expected close at the end of the second quarter of 2027. The issue was fit, not health. After a decade of conglomerate-building through large mergers, IFF concluded it could not fund the division’s capital needs while also investing behind its higher-margin scent, taste, and biosciences businesses. So it chose to refocus, retaining roughly a 10% stake and taking about $3.8 billion in net cash proceeds, much of it earmarked for debt reduction.
What CVC is buying is defensibility. Specialty ingredients are embedded deep in customers’ formulations and production lines. Once a texturant or emulsifier is designed into a product and cleared by quality and regulatory teams, replacing it is slow and expensive. That produces sticky relationships, reformulation know-how that compounds over time, and switching costs that suppress customer churn. For a sponsor underwriting cash-flow durability rather than top-line fireworks, a scaled, capital-starved but defensible ingredients platform is close to an ideal asset.
Now the buyer. On May 14, Ingredion confirmed it was weighing a possible all-cash offer for Tate & Lyle under Rule 2.6 of the UK Takeover Code, starting a clock that required it to commit or walk away by June 11. It committed. On June 8, Ingredion announced a firm, board-recommended all-cash acquisition at 595 pence per share, an approximate 59% premium to Tate & Lyle’s pre-approach closing price, valuing the equity at about £2.7 billion ($3.6 billion) and the enterprise at roughly £3.7 billion ($5.0 billion). The combination pairs Tate & Lyle’s strength in sweetening, mouthfeel, and fortification with Ingredion’s texturants and sugar-reduction systems, creating one of the largest specialty ingredients platforms in the world, with combined revenue near $10 billion. Completion is not immediate and remains subject to shareholder and regulatory approval, but this is an agreed transaction, not a rumor.
Read together, the two deals describe a single repricing. One company is shedding an ingredients business and the other is buying one, yet both buyers are paying for the same thing: control of the defensible, reformulation-critical chemistry that food and beverage manufacturers cannot easily switch away from. CVC is acquiring that defensibility as a standalone cash engine. Ingredion is acquiring it as scale, betting that a broader toolkit makes it a more indispensable single supplier to customers reformulating across sugar, texture, fiber, and protein at the same time.
The common driver is structural. Consumer demand for better-for-you products, the regulatory pressure crystallized by the Make America Healthy Again agenda, and the protein-and-satiety shift accelerated by GLP-1 adoption are all pushing brands toward continuous reformulation. The suppliers that enable that reformulation occupy something like a toll road. Whichever consumer brands ultimately win the clean-label contest, the ingredient platform underneath gets paid. That is why a sponsor will underwrite a carve-out at ten times EBITDA and a strategic will pay a 59% premium in the same month.
The takeaway for owners and acquirers is straightforward. In ingredients, capital is concentrating around two attributes, defensibility and scale, and it will arrive through either de-conglomeration or consolidation to secure them. Expect more strategics to free trapped ingredient assets into the hands of sponsors, and more sponsors and strategics to compete for the pure-play platforms that already have both. The brand layer will keep making the headlines. The layer below it is where this cycle is quietly being underwritten.
|
— deal metrics —
|
IFF → CVC Capital
|
|
$4.3B
Transaction Value
|
~10x
EV / EBITDA
|
|
$3.1B
Division Revenue (2025)
|
~10%
IFF Retained Equity
|
|
|
|
Ingredion → Tate & Lyle
|
|
$5.0B
Enterprise Value
|
59%
Offer Premium
|
|
$7.47/sh
Per Share (All-Cash)
|
~$10B
Combined Revenue
|
|
Sources: IFF 8-K (SEC EDGAR, June 1, 2026) · Ingredion 8-K EX-99.1 (SEC EDGAR, May 14, 2026) · Ingredion RNS (June 8, 2026)
|
|
— takeaways —
|
i.
Two directions at once: IFF is selling to PE, Ingredion is buying. Both reflect the same thesis. Scale and focus beat diversified conglomerates in specialty ingredients.
|
ii.
Neither deal is distress. Both buyers are paying up for defensibility, reformulation IP, and customer switching costs. That is the new underwriting thesis in food ingredients.
|
iii.
More of this is coming. Expect strategics to shed more trapped ingredient assets and sponsors and strategics to compete for pure-play platforms that already have scale and defensibility.
|
|
|
